Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse

Anum Saeed, Salim S. Virani, Peter H. Jones, Christie M. Ballantyne, Vijay Nambi

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduces low-density lipoprotein cholesterol levels and improves cardiovascular outcomes. Given the short time frame, these agents have been available for use; reports of nonresponse to the PCSK9 inhibitor therapy are scarce in literature. We describe 2 cases with substantially lesser than expected low-density lipoprotein cholesterol lowering on PCSK9 therapy. Nonresponse to PCSK9 inhibition was attributed to autosomal recessive hypercholesterolemia (secondary to low-density lipoprotein receptor adaptor protein 1 mutation) and plasmapheresis after PCSK9 inhibitor drug injections. Additional PCSK9 inhibitor nonresponders are likely to emerge as the use of these agents increases overtime.

Original languageEnglish
Pages (from-to)1141-1145
Number of pages5
JournalJournal of Clinical Lipidology
Issue number5
Publication statusPublished - 1 Sept 2018
Externally publishedYes


  • Cardiovascular diseases
  • Coronary artery disease
  • Dyslipidemia
  • Hypercholesterolemia
  • PCSK9 inhibitors


Dive into the research topics of 'Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse'. Together they form a unique fingerprint.

Cite this